DSIP gets plenty of attention from people looking for better sleep. What gets less attention is how much the online protocols differ. Some describe nightly use. Others include days off, an earlier evening window, or a break between cycles.
I want to make those differences easy to follow. This DSIP dosage guide covers the subcutaneous schedule reported in online peptide protocols, explains the numbers on a vial, and looks at what the sleep research can actually tell us. The schedule below is reported community practice, not an established medical treatment.
What Is DSIP?
DSIP stands for delta sleep-inducing peptide. It is a nine-amino-acid peptide studied in relation to sleep and other physiological processes. You may also see it called emideltide.
The name sounds more settled than the research is. DSIP has an interesting history, but the available studies do not establish a reliable subcutaneous treatment for insomnia. That makes the route, the study design, and the actual outcomes worth checking before accepting broad claims about deep sleep.
DSIP Dosage: The Reported Subcutaneous Protocol
The online protocol reviewed for this guide describes 250 mcg by subcutaneous injection, 1–3 hours before bed, five nights on and two nights off. It describes an eight-week period followed by eight weeks off. These are the amounts and timing reported by that protocol, rather than a recommendation to administer a research material.
| Amount | 250 mcg / 0.25 mg |
|---|---|
| Reported route | Subcutaneous |
| Timing | 1–3 hours before bed |
| Weekly pattern | Five nights on, two nights off |
| Cycle described | Eight weeks, followed by eight weeks off |
| Evidence status | Reported community schedule; not a validated clinical regimen |
Other online guides describe 100–300 mcg nightly, often closer to bedtime. Those differences tell us that there is no agreed subcutaneous standard. They do not prove that a higher amount, a longer cycle, or more frequent use gives better sleep.
DSIP Timing and Cycle Length
The schedule above uses an evening window of one to three hours before bed. That is the timing reported in the source protocol. It should not be presented as a proven onset time or a guarantee that sleep will improve within that window.
The same distinction applies to five nights on and two off, and to the eight-week break. These are features of the online schedule. The cited clinical literature does not establish that those intervals prevent tolerance or provide the best balance of benefit and risk.
This is where I think tracking is more useful than promising a result. Time taken to fall asleep, nighttime waking, and next-day alertness describe different parts of sleep. A single good night does not establish what caused it, especially when bedtime, caffeine, alcohol, stress, or other compounds changed too.
DSIP Vial Math: Milligrams, Micrograms and Units
The first distinction is between the amount in the whole vial and the amount in a measured volume. A 10 mg vial contains 10,000 mcg in total. It does not contain ten doses unless each calculation is for 1 mg.
For illustration, 10 mg at a final solution volume of 2 mL gives a concentration of 5 mg/mL. On a U-100 scale, one unit is 0.01 mL, which contains 50 mcg at that concentration. A calculated quantity of 250 mcg therefore occupies 0.05 mL, or five U-100 units.
| Vial amount | Final volume | Concentration | Volume / U-100 markings |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 0.10 mL / 10 units |
| 10 mg | 2 mL | 5 mg/mL | 0.05 mL / 5 units |
| 10 mg | 3 mL | 3.33 mg/mL | 0.075 mL / 7.5 units |
These examples check arithmetic. They do not establish suitability for injection, a preparation method, sterility, or a storage life. Half-unit markings are not present on every syringe, and rounding a marking changes the calculated amount.
The peptide calculator can check other concentrations. The reconstitution guide explains how vial amount, final volume, and concentration relate.
What Does DSIP Sleep Research Show?
Small human studies from the earlier DSIP research program explored sleep-related outcomes. A six-volunteer study reported changes in sleep after administration, including later nighttime measures. Another controlled chronic-insomnia study is part of that evidence record. These experiments used a different administration route from the subcutaneous schedule discussed here.
I would not use those studies to promise that a 250 mcg subcutaneous schedule increases deep sleep by a particular percentage. A positive result in one experiment does not establish the same effect across routes, populations, and schedules. DSIP’s biological role and clinical usefulness also remain unsettled.
The important question is whether the exact regimen being described was tested. For this community injection schedule, that link has not been established. No IV dosage or IV-to-subcutaneous conversion is used in the calculations above.
DSIP Side Effects and Safety
The information available is not enough to estimate reliable side-effect rates for this subcutaneous schedule. Online reports mention headache, nausea, dizziness, and injection-site discomfort, but anecdotes cannot determine how common a reaction is or whether DSIP caused it.
FDA’s assessment of emideltide raised concerns about insufficient safety information, peptide impurities and possible immune reactions. Its review did not find adequate evidence of effectiveness for the evaluated sleep disorders. Claims that DSIP is harmless or has a proven wide safety margin for repeated subcutaneous use would go further than that assessment supports.
Persistent insomnia deserves a proper assessment, particularly when snoring, breathing pauses, marked daytime sleepiness, mood symptoms, or medication effects are part of the picture. A research peptide protocol is not a substitute for identifying the cause.
DSIP Storage and Handling
Follow the documentation for the exact material, formulation and preparation. A generic statement about keeping peptides in the refrigerator does not establish how long a particular mixed DSIP vial remains stable or sterile.
Concentration calculations also assume that the stated amount and final volume are correct. Appearance alone cannot confirm identity, potency, purity, or sterility. The number of theoretical quantities available from a vial should never be used as a shelf-life guarantee.
DSIP Dosage Questions
Is 250 mcg the same as 0.25 mg?
Yes. One milligram equals 1,000 micrograms, so 250 mcg equals 0.25 mg. That quantity is separate from the liquid volume needed to contain it.
Does a 5 mg vial require a different DSIP protocol?
Vial size changes the available amount and, depending on final volume, the concentration. It does not by itself establish a different biological dose or cycle. The table above shows why the same quantity can correspond to different volume markings.
Is DSIP used every night?
Some online guides describe nightly use. The protocol summarized on this page describes five nights on and two nights off. Neither pattern should be described as a clinically established standard.
Is the eight-week cycle proven?
No. Eight weeks on followed by eight weeks off is part of the reported community protocol. It is not a duration established by a controlled trial of that subcutaneous schedule.
Can DSIP be combined with other sleep peptides?
Combining compounds makes it harder to identify effects and adverse reactions. The sources reviewed here do not establish the safety or effectiveness of a DSIP sleep stack. Separate evidence about two ingredients does not prove the combined schedule.
Sources
- Online community protocol reference for the 250 mcg schedule.
- Acute and delayed effects of DSIP on human sleep behavior: a small historical human study.
- FDA assessment of emideltide-related substances, including the proposed subcutaneous route.
- FDA compounding advisory presentation: evidence and safety assessment.
- Example of differing community-reported DSIP schedules and concentration calculations.
Joe Mars · The Peptide Report
